Stay in the Know
Get the latest news on exciting speakers, workshops & learning opportunities at ICNMD 2021.
The following industry-supported symposia, organized by ICNMD 2021 sponsors, will be broadcast live on the following days and times. Click on the tabs below to read more.
During ICNMD 2021 Live Days, you will find these symposia listed chronologically in the 'Industry Sessions' section of the virtual platform.
Starting May 17, you may also click on the dedicated symposium links [which will be provided below] to be taken directly to each symposium page. You will need to log in with your platform credentials (to be sent on May 17 to ICNMD 2021 registered delegates).
![]() |
Generalised Myasthenia Gravis (gMG) 360: From Cause to Consequence Time: 12:00 - 12:45 CEST Agenda
|
![]() |
A Novel Assessment of Swallowing in SMA: Insights from the NURTURE Study Time: 12:00 - 12:20 CEST Agenda
|
![]() |
Current Treatment Landscape of Myotonia in Muscle Channelopathies: Focus on Mexiletine Time: 12:25 - 12:45 CEST Agenda Speaker: Prof Savine Vicart, University Hospital Pitié-Salpêtrière, France
|
![]() |
Gene Therapy – Transforming the Clinical Outlook for Neuromuscular Diseases Time: 17:15 - 18:00 CEST Agenda
|
![]() |
How to Overcome Challenges in Pompe Disease Management During the COVID-19 Era Time: 17:15 - 18:00 CEST Agenda
|
![]() |
Case Studies of Intrahepatic Cholestasis in X-linked Myotubular Myopathy Time: 12:00 - 12:45 CEST Agenda
|
![]() |
Meaningful Outcomes Across All SMA Types Time: 12:00 - 12:45 CEST Agenda
|
![]() |
Serum Autoantibody Levels and the Role of Specificity in Myasthenia Gravis Time: 16:15 - 17:00 CEST |
![]() |
Industry-Supported Symposium by Sarepta Therapeutics Time: 16:15 - 17:00 CEST |
![]() |
Can We Regain Control? A Clinical Case-Based Discussion on the Treatment of Refractory Generalized Myasthenia Gravis Time: 12:00 - 12:45 CEST Agenda
|
![]() |
A Unique Pregnancy Case: Venturing Beyond the Norms in Pompe Disease Time: 12:00 - 12:20 CEST Agenda Speakers: Prof. Priya Kishnani, Professor of Pediatrics, Duke Department of Pediatrics, USA (chair & speaker)
|
![]() |
What Matters? Setting Treatment Expectations in SMA Type 1 Time: 12:25 - 12:45 CEST Agenda
|
![]() |
Understanding the Immunomodulatory Effects and Clinical Benefits of IVIG in Myasthenia Gravis Time: 16:15 - 17:00 CEST Agenda
|
![]() |
Advancing the Management of Duchenne Muscular Dystrophy: The Disease Continuum and Transition from Pediatric to Adult Care Time: 16:15 - 17:00 CEST Agenda
|
![]() |
Pathways and Paradigms in ALS: Life and Death in the Neuron Time: 12:00 - 12:45 CEST Agenda
|
![]() |
Suspecting, Diagnosing, and Managing Multifocal Motor Neuropathy: A Patient Investigation Time: 17:15 - 18:00 CEST Agenda
|
![]() |
Gene Transfer Therapy: Addressing the Unmet Needs of Duchenne Muscular Dystrophy (DMD) Time: 17:15 - 17:35 CEST Agenda Speaker: Professor Wolfgang Müller-Felber, Dr von Hauner Children’s Hospital, Germany
|